TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma

Qinghong Li(Shanghai FRP Research Institute (China)), Hongyuan Liang(Shanghai FRP Research Institute (China)), Aidong Qu(Shanghai FRP Research Institute (China)), Jingyi Xu(First Hospital of China Medical University), Wenyan Shen(Lanzhou University), Kunming Zhang(Shanghai FRP Research Institute (China)), Zeng Yu(Shanghai FRP Research Institute (China)), Yu Yao(Qinghai University)
PLoS ONE
September 25, 2024
Cited by 0


Related Papers